Therapeutic effects of astrocytes expressing both tyrosine hydroxylase and brain-derived neurotrophic factor on a rat model of Parkinson's disease

Neuroscience

Volumn 113, Issue 3, 2002, Pages 629-640

  Wang, Z H ^a   Ji, Y ^a   Shan, W ^b   Zeng, B ^a   Raksadawan, N ^a   Pastores, G M ^a   Wisniewski, T ^a   Kolodny, Edwin H ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Astrocytes; Brain derived neurotrophic factor; Gene therapy; Parkinson's disease; Tyrosine hydroxylase

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; OXIDOPAMINE; RETROVIRUS VECTOR; TYROSINE 3 MONOOXYGENASE; DOPAMINE; MESSENGER RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; ASTROCYTE; CELL SURVIVAL; CIRCLING BEHAVIOR; CONTROLLED STUDY; CONVALESCENCE; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; ENZYME ACTIVITY; EXPRESSION VECTOR; GENE THERAPY; GENETIC TRANSFECTION; MALE; NEUROPROTECTION; NEWBORN; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SURVIVAL TIME; SYMPTOM; ANIMAL; ANIMAL BEHAVIOR; CHEMICALLY INDUCED DISORDER; CULTURE TECHNIQUE; DISEASE MODEL; GENE VECTOR; GENETICS; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; METABOLISM; METHODOLOGY; PARKINSONISM; PATHOLOGY; RETROVIRUS; SUBSTANTIA NIGRA; TIME; WESTERN BLOTTING;

ANIMAL; APOPTOSIS; ASTROCYTES; BEHAVIOR, ANIMAL; BLOTTING, WESTERN; BRAIN-DERIVED NEUROTROPHIC FACTOR; CELL CULTURE; CELL SURVIVAL; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE; GENE THERAPY; GENETIC VECTORS; IMMUNOHISTOCHEMISTRY; OXIDOPAMINE; PARKINSONIAN DISORDERS; RATS; RETROVIRIDAE; RNA, MESSENGER; SUBSTANTIA NIGRA; SUPPORT, NON-U.S. GOV'T; TIME FACTORS; TRANSFECTION; TYROSINE 3-MONOOXYGENASE; ANIMALS; CELL CULTURE TECHNIQUES;

EID: 0037008876     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4522(02)00204-X     Document Type: Article

References (52)

1. Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease
2. Brain-derived neurotropic factor-mediated protection of striatal neurons in an excitotoxic rat model of Huntington's disease, as demonstrated by adenoviral gene transfer
3. Attenuation of 6-OHDA-induced neurotoxicity in glutathione peroxidase transgenic mice
4. Brain-derived neurotropic factor mediates the anti-apoptotic effect of NMDA in cerebellar granule neurons: Signal transduction cascades and site of ethanol action
5. Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: Contribution to the apoptotic theory in Parkinson's disease
6. Gene therapy for Parkinson's disease
7. Gene therapy of Parkinson's disease model rat by direct injection of plasmid DNA-lipofection complex
8. Dopaminergic neurons protected from degeneration by GDNF gene therapy
9. Brain-derived neurotropic factor induces a rapid upregulation of synaptophysin and tau proteins via the neurotrophin receptor TrκB in rat cerebellar granule cells
10. Neurotrophins protect cultured cerebellar granule neurons against the early phase of cell death by a two-component mechanism
11. Possible extrapyramidal system degradation in Parkinson's disease
12. Long-term behavioral recovery in Parkinsonian rats by an HSV vector expressing tyrosine hydroxylase
13. Behavioral recovery in 6-hydroxydopamine-lesioned rats by cotransduction of striatum with tyrosine hydroxylase and aromatic L-amino acid decarboxylase genes using two separate adeno-associated virus vectors
14. Transplantation of embryonic dopamine neurons for sever Parkinson's disease
15. Implanted fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevent 1-methyl-4-phenylpyridinium toxicity to dopaminergic neurons in the rat
16. Dopaminergic neurons degenerate by apoptosis in Parkinson's disease
17. Gene therapy for Parkinson's disease
18. 6-hydroxydopamine lesion of the rat substantia nigra: Time course and morphology of cell death
19. Decarboxylation of L-dopa by cultured mouse astrocytes
20. Prevention of apoptotic motoneuron death in vitro by neurotrophins and muscle extract
21. Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain
22. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease
23. Time course of striatal changes induced by 6-hydroxydopamine of the nigrostriatal pathway, as studied by combined evaluation of rotational behavior and striatal Fos expression
24. Aspartoacylase gene transfer to the mammalian central nervous system with therapeutic implications for Canavan disease
25. Tetrahydrobiopterin in striatum: Localization in dopamine nerve terminals and role in catecholamine synthesis
26. Intrastriatal implantation of fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevents degeneration of dopaminergic neurons in a rat model of Parkinson's disease
27. BDNF-transduced fibroblasts: Production of BDNF and effects of grafting to the adult rat brain
28. The cause of Parkinson's disease are being unraveled and rational neuroprotective therapy is close to reality
29. Early developmental destruction of terminals in the striatal target induces apoptosis in dopamine neurons of the substantia nigra
30. Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression
31. Improved retroviral vectors for gene transfer and expression
32. Histochemical detection of apoptosis in Parkinson's disease
33. Brain-derived neurotrophic factor in the control human brain, and in Alzheimer's disease and Parkinson's disease
34. Signaling pathways and survival effects of BDNF and NT-3 on cultured cerebellar granule cells
35. Overexpression of HA-Bax but not Bcl-2 or Bcl-X1 attenuates 6-hydroxydopamine-induced neuronal apoptosis
36. An acid-treatment method for the enhanced detection of GDNF in biological samples
37. Toward autologous ex vivo gene therapy for the central nervous system with human adult astrocytes
38. Abnormal cerebellar development and foliation in BDNF-/- mice reveals a role for neurotrophins in CNS patterning
39. Triple transduction with adeno-associated virus vectors expressing tyrosine hydroxylase, aromatic-L-amino-acid decarboxylase, and GTP cyclohydrolase I for gene therapy of Parkinson's disease
40. The use of nonneuronal cells for gene delivery
41. Brain-derived neurotropic factor protects dopamine neurons against 6-hydroxydopamine and N-methyl-4-phenylpyridinium ion toxicity involvement of the glutathione system
42. Brain-derived neurotropic factor suppresses programmed death of cerebellar granule cells through a posttranslational mechanism
43. A fluorescent double-labeling method to detect and confirm apoptotic nuclei in Parkinson's disease
44. GDNF reduces drug-induced rotational behavior after medial forebrain bundle transection by a mechanism not involving striatal dopamine
45. Tetrahydrobiopterin dependent functional recovery in 6-hydroxydopamine-treated rats by intracerebral grafting of fibroblasts transfected with tyrosine hydroxylase cDNA
46. Correlation of glioma cell regression with inhibition of insulin-like growth factor (IGF) 1 and IGF binding protein-2 expression
47. In vivo and in vitro glioma cell killing induced by an adenovirus expressing both cytosine deaminase and thymidine kinase and its association with interferon-α
48. Site-directed mutagenesis of tyrosine hydroxylase
49. Insulin receptor substrate (IRS)-1 and IRS2 are tyrosine-phosphorylated and associated with phosphatidylinositol 3-kinase in response to brain-derived neurotropic factor in cultured cerebral cortical neurons
50. Astrocytes retrovirally transduced with BDNF elicit behavioral improvement in a rat model of Parkinson's disease
51. Time course of degenerative alterations in nigral dopaminergic neurons following a 6-hydroxydopamine lesion